RJFSA
TERN

Raymond James Financial Services Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,830
Closed -$123K – 3383
2022
Q3 		$123K Buy
+20,830
New +$77.4K ﹤0.01% 2963

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raymond James Financial Services Advisors's TERN Position: Q4 2022 in Review

Raymond James Financial Services Advisors sold out of Terns Pharmaceuticals (TERN) in Q4 2022, closing a stake of 20,830 shares — an estimated $123K sold.

Raymond James Financial Services Advisors first reported a position in TERN in Q3 2022 and held it in 1 quarter. The position peaked at $123K in Q3 2022. 65 funds tracked by Wall St. Rank hold TERN as of Q4 2022.

  • Raymond James Financial Services Advisors reported no remaining Terns Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 20,830 Terns Pharmaceuticals shares in Q4 2022, an estimated $123K.
  • Raymond James Financial Services Advisors first reported a position in Terns Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Terns Pharmaceuticals position peaked at $123K in Q3 2022.
  • 65 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.